Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan Sells 1,730 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 1,730 shares of the company’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $29.96, for a total value of $51,830.80. Following the transaction, the chief financial officer now directly owns 86,370 shares of the company’s stock, valued at approximately $2,587,645.20. This represents a 1.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Monday, January 13th, Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total value of $62,279.00.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS opened at $30.13 on Wednesday. The firm has a market cap of $3.75 billion, a price-to-earnings ratio of -14.84 and a beta of 0.94. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a 1-year low of $24.34 and a 1-year high of $71.90. The firm’s fifty day moving average price is $31.89 and its 200 day moving average price is $33.31.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The firm had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company’s revenue was up 78.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.17) earnings per share. On average, sell-side analysts expect that Apellis Pharmaceuticals, Inc. will post -1.71 EPS for the current year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Envestnet Asset Management Inc. boosted its stake in shares of Apellis Pharmaceuticals by 42.2% in the second quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock valued at $5,161,000 after buying an additional 39,931 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock valued at $112,036,000 after acquiring an additional 735,160 shares during the period. Profund Advisors LLC boosted its position in shares of Apellis Pharmaceuticals by 90.7% during the 2nd quarter. Profund Advisors LLC now owns 42,968 shares of the company’s stock worth $1,648,000 after purchasing an additional 20,435 shares in the last quarter. Algert Global LLC grew its stake in shares of Apellis Pharmaceuticals by 137.8% during the 2nd quarter. Algert Global LLC now owns 123,628 shares of the company’s stock worth $4,742,000 after purchasing an additional 71,650 shares during the period. Finally, AlphaCentric Advisors LLC acquired a new position in shares of Apellis Pharmaceuticals during the 3rd quarter worth $1,370,000. 96.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on APLS. Robert W. Baird cut their price objective on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Bank of America cut their price target on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Wells Fargo & Company decreased their price objective on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Citigroup cut their target price on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Finally, William Blair initiated coverage on Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They issued an “outperform” rating for the company. Eight research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $46.71.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).